Clinical Trials Sponsored by EuBiologics Co.,Ltd

Total 10228 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

IBI188 Combination Therapy in Solid Tumors

Osteosarcoma | Lung Adenocarcinoma | Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Neovascular Age-related Macular Degeneration

China
Synermore Biologics (Suzhou) Co., Ltd.

Completed

A Bridging Study of the SYN023 on Healthy Adult Subjects

Vaccine Reaction | Rabies Human | Immunisation Reaction | Zoonotic Disease | Communicable Disease Transmission

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Overweight/Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients (ORIENT-4)

Effect of Drugs

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

MDS

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

B-Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI363 in Subjects With Advanced Solid Malignancies

Solid Tumors

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Healthy Participants | Atopic Dermatitis Patients

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
Zhejiang Doer Biologics Co., Ltd.

Recruiting

A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors

Malignant Neoplasm of Digestive System

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Zhejiang Doer Biologics Co., Ltd.

Recruiting

A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

Healthy, Obesity, Metabolically

New Zealand
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Diffuse Large B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Hematologic Malignancy

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Intense Monitoring Study on Tyvyt

Relapsed or Refractory Classical Hodgkin's Lymphoma

China
Starmab biologics（Shanghai）Co,.ltd

Active, not recruiting

A Phase I Study of XJ101 in Chinese Healthy Subjects

Staphylococcus Aureus Bloodstream Infection

China
Starmab biologics（Shanghai）Co,.ltd

Active, not recruiting

A Phase I Study of XJ103 in Chinese Healthy Subjects

Pneumococcal Disease

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Gout Arthritis

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Thyroid Eye Disease

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of [14C]IBI351 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI351 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Healthy Volunteers

Healthy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Advanced Malignant Tumors Lymphomas

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Obesity or Overweight

Obesity Or Overweight

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

CLDN18.2 Positive Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Gastric Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China

3

Subscribe